Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG777 Long-term Extension Study in Atopic Dermatitis
NCT07003425Phase 2Recruiting
- Sponsor
- Apogee Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2029
- Modality
- IgG Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of apg777 in atopic dermatitis (AD), sponsored by Apogee Therapeutics. Started May 2025; status: recruiting.
02
Drugs
apg777
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07003425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003425.